AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
NEWARK, Calif., May 01, 2018 -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Tuesday, May 8, 2018 at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2018 and to provide a business update.
Conference Call Details
To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13678369. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at http://ir.cymabay.com/events.
About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with nonalcoholic steatohepatitis (NASH). Two Phase 2 studies of seladelpar established proof of concept in PBC. CymaBay is currently planning to advance development of seladelpar into Phase 3 for PBC and Phase 2 for NASH.
For additional information about CymaBay visit www.cymabay.com.
Contact:
Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568
[email protected]
